The doubling of positions by 4 active asset managers signals conviction in Abivax's pipeline, but the 45-day 13F lag means these positions may already be unwound. Monitor for insider buying (currently absent) and upcoming clinical catalysts to confirm the thesis. The mixed net direction and lack of activist involvement suggest this is a gradual accumulation pattern, not a catalyst-driven event.
Executive Summary
Four institutional investors doubled their ABVX positions in Q2 2026, led by Pictet Asset Management ($54.4M increase) and Erste Asset Management ($5.5M increase), while two institutions trimmed. The cluster is dominated by active asset managers, suggesting a shared positive thesis on Abivax's pipeline or commercial prospects, but the lack of insider buying and the 45-day reporting lag temper conviction. The net $64.3M buying inflow is notable for a $10.8B market cap stock, but the mixed net direction and absence of insider corroboration warrant caution.
Key Financial Metrics
Institutional Positions
Net institutional flow: $59.1M
▲ Buyers (4)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Pictet Asset Management Holding | DOUBLED | +375.2% | $65.6M | $54.4M |
| Erste Asset Management | DOUBLED | +120% | $10.6M | $5.5M |
| Walleye Capital | DOUBLED | +268.1% | $4.2M | $3.3M |
| Citigroup | DOUBLED | +481.9% | $1.3M | $1.1M |
▼ Sellers (2)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Td Asset Management | TRIM | -74.1% | $7.3M | -$5.0M |
| Walleye Trading | TRIM | -30.5% | $1.1M | -$182.9K |
Key Facts
- 4 institutions doubled ABVX positions in Q2 2026, adding $64.3M in net buying value
- Pictet Asset Management was the largest buyer, increasing holdings by $54.4M (375% increase)
- 2 institutions trimmed positions, with TD Asset Management reducing by $5.0M (74% decrease)
- No open-market insider buying detected in the same period (confluence score 30/100)
- All 6 funds are categorized as asset managers — no activist or hedge fund names in the cluster
- ABVX has 86% analyst bullish rating (6 Strong Buy, 6 Buy, 2 Hold)
Financial Impact
4 institutional buyers added $64.3M in new position value, while 2 sellers reduced by $5.2M, for net institutional inflow of approximately $59.1M
Risk Factors
- 13F data is 45+ days stale — positions may have been partially or fully exited since quarter-end
- No insider buying to corroborate the institutional thesis
- Mixed net direction (4 buyers vs 2 sellers) reduces signal clarity
- Historical T+20 performance on ABVX reports is flat (-0.01% average), suggesting limited near-term alpha
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-ABVX-2026-Q2 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Institutional Cluster | $130.00 $114.04 | ▼ −12.28% | ▼ −12.88% | — |
Jul 2, 2026 13w ago | 6-K | $144.65 $124.33 | ▲ +14.05% | ▲ +13.63% | — |
Jul 2, 2026 13w ago | 424B5 | $144.65 $124.33 | ▲ +14.05% | ▲ +13.63% | — |
Jul 1, 2026 13w ago | Press Release | $132.56 $118.84 | ▲ +10.35% | ▲ +8.16% | — |
Jun 29, 2026 13w ago | 6-K | $133.26 $128.00 | ▼ −3.95% | ▼ −2.92% | — |
Jun 29, 2026 13w ago | Press Release | $133.26 $128.00 | ▼ −3.95% | ▼ −2.92% | — |
May 22, 2026 18w ago | Press Release | $126.41 $94.01 | ▼ −25.63% | ▼ −23.68% | — |
Mar 23, 2026 27w ago | Press Release | $110.17 $115.99 | ▲ +5.28% | ▼ −3.62% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access